摘要
背景:该研究有两个目的(1)为了评估在正常认知人群神经心理功能的变化,其也许先于临床症状的发作。(2)为了检测载脂蛋白E (ApoE )基因对这些变化的影响。方法:268名认知正常的人预期完成了纵向神经心理、临床评估和达成一致的诊断。平均随访时间为9.2年(+/- 3.3)。208名参与者依然正常,60参与者已发展为认知障碍,与MCI或者痴呆的诊断一致。完成了对基准率分数和分数的变化率Cox 回归分析,涉及临床症状发作时间的关系。对ApoE-4携带者或非携带者状态进行了分析。检测了与ApoE-4 状态的反应。结果:较低的基准测试分数和变化率测试分数与临床症状发作时间有一定关联(P<0.001)。基线到临床症状发作的平均时间是6.15 (+/- 3.4)。ApoE-4基因存在加倍进展的风险。在这两项测试中,ApoE-4携带者和非携带者分数的变化率有显著区别。 结论:认知衰退遭遇临床症状的发作,可以作为MCI前兆诊断。正常人持续的认知衰退变化也许至少6.5年才可以观察到,但是先于症状发作。此外,ApoE-4基因携带者有双倍的衰退风险。
关键词: 载脂蛋白E基因,认知衰退,情景记忆,纵向随访,轻度认知功能障碍,临床前阿尔茨海默病
Current Alzheimer Research
Title:Cognitive Changes Preceding Clinical Symptom Onset of Mild Cognitive Impairment and Relationship to ApoE Genotype
Volume: 11 Issue: 8
Author(s): Marilyn Albert, Anja Soldan, Rebecca Gottesman, Guy McKhann, Ned Sacktor, Leonie Farrington, Maura Grega, Raymond Turner, Yi Lu, Shanshan Li, Mei-Cheng Wang and Ola Selnes
Affiliation:
关键词: 载脂蛋白E基因,认知衰退,情景记忆,纵向随访,轻度认知功能障碍,临床前阿尔茨海默病
摘要: Background: This study had two goals (1) to evaluate changes in neuropsychological performance among cognitively normal individuals that might precede the onset of clinical symptoms, and (2) to examine the impact of Apolipoprotein E (ApoE) genotype on these changes. Methods: Longitudinal neuropsychological, clinical assessments and consensus diagnoses were completed prospectively in 268 cognitively normal individuals. The mean duration of follow-up was 9.2 years (+/- 3.3). 208 participants remained normal and 60 developed cognitive decline, consistent with a diagnosis of MCI or dementia. Cox regression analyses were completed, for both baseline scores and rate of change in scores, in relation to time to onset of clinical symptoms. Analyses were completed both with and without ApoE-4 status included. Interactions with ApoE-4 status were also examined. Results: Lower baseline test scores, as well as greater rate of change in test scores, were associated with time to onset of clinical symptoms (p<0.001). The mean time from baseline to onset of clinical symptoms was 6.15 (+/- 3.4) years. The presence of an ApoE-4 allele doubled the risk of progression. The rate of change in two of the test scores was significantly different in ApoE-4 carriers vs. non-carriers. Conclusions: Cognitive performance declines prior to the onset of clinical symptoms that are a harbinger of a diagnosis of MCI. Cognitive changes in normal individuals who will subsequently decline may be observed at least 6.5 years prior to symptom onset. In addition, the risk of decline is doubled among individuals with an ApoE-4 allele.
Export Options
About this article
Cite this article as:
Marilyn Albert, Anja Soldan, Rebecca Gottesman, Guy McKhann, Ned Sacktor, Leonie Farrington, Maura Grega, Raymond Turner, Yi Lu , Shanshan Li, Mei-Cheng Wang and Selnes Ola, Cognitive Changes Preceding Clinical Symptom Onset of Mild Cognitive Impairment and Relationship to ApoE Genotype, Current Alzheimer Research 2014; 11 (8) . https://dx.doi.org/10.2174/156720501108140910121920
DOI https://dx.doi.org/10.2174/156720501108140910121920 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Blood-Brain Barrier P-Glycoprotein Function in Neurodegenerative Disease
Current Pharmaceutical Design Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Anti-Inflammatory Therapy for Alzheimer’s Disease from Epidemiological Fact to New Mechanisms of Action
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Repetitive Transcranial Magnetic Stimulation Reverses Aβ1–42-induced Dysfunction in Gamma Oscillation during Working Memory
Current Alzheimer Research Opioids and Opioid Maintenance Therapies: Their Impact on Monocyte-Mediated HIV Neuropathogenesis
Current HIV Research LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
Current Neuropharmacology NAP (Davunetide) Provides Functional and Structural Neuroprotection
Current Pharmaceutical Design Microglial dependent protective effects of neuroactive steroids
CNS & Neurological Disorders - Drug Targets Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Neuron-to-microglia Crosstalk in Psychiatric Disorders
Current Neuropharmacology Commentary: Toward a Personalized Medicine in Wake-Up Stroke?
CNS & Neurological Disorders - Drug Targets NMDA Receptor Antagonists: Repositioning of Memantine as a Multitargeting Agent for Alzheimer's Therapy
Current Pharmaceutical Design Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Protein Kinase C Isozymes: Memory Therapeutic Potential
Current Drug Targets - CNS & Neurological Disorders Disturbance of Inorganic Phosphate Metabolism in Diabetes Mellitus: Its Impact on the Development of Diabetic Late Complications
Current Diabetes Reviews The Clinical Utility of Ambulatory Blood Pressure Monitoring (ABPM): A Review
Current Hypertension Reviews Design, Sar, and Metabolism Study of Crucifereae Family Compound (Spirobrassinin) and its Analogs for Antiangiogenic Potential Targeting Hsp90
Current Proteomics Inhibition of Glycogen Synthase Kinase-3 Reverses Tau Hyperphosphorylation Induced by Pin1 Down-Regulation
CNS & Neurological Disorders - Drug Targets DLPF Targeted Repetitive Transcranial Magnetic Stimulation Improves Brain Glucose Metabolism Along with the Clinical and Electrophysiological Parameters in CBD Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets